What is the proper protocol for administering Intravenous Immunoglobulin (IVIG)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Intravenous Immunoglobulin (IVIG) Administration Protocol

IVIG should be administered at 1-2 g/kg of ideal body weight, usually given over 2 consecutive days (1 g/kg each on day 1 and day 2) for most autoimmune conditions, with dosing adjusted based on specific indications. 1, 2

Pre-Administration Assessment

  • Check serum IgA level before administering IVIG to prevent fever, infusion reactions, or severe anaphylaxis in patients with IgA deficiency 1, 2
  • If IgA deficiency is detected, use an IVIG preparation with reduced IgA levels 1, 2
  • Review patient's medical history for risk factors such as renal dysfunction, thrombotic risk, or history of previous infusion reactions 1

Dosing Guidelines by Indication

  • Immunodeficiency disorders: 300-400 mg/kg IV monthly for replacement therapy 2, 3
  • Idiopathic Inflammatory Myopathies: 1-2 g/kg of ideal body weight, usually given over 2 consecutive days 1, 2
  • Immune Thrombocytopenic Purpura (ITP): 1 g/kg as a one-time dose, which may be repeated if necessary 2, 4
  • Kawasaki Disease: 2 g/kg IV as a single infusion 1, 2
  • Myasthenia Gravis: Initial infusion of 400 mg/kg/day for 5 days followed by maintenance therapy of 400 mg/kg for 1 day every 3-4 months 5
  • Antibody-mediated rejection in cardiac transplantation: Varies by center protocol, typically 500 mg/kg IV once daily for 4 days or 2 g/kg divided into 2 doses over 2 consecutive days 1

Administration Technique

  • For standard doses (≤80 g), administer over 2 consecutive days 1, 2
  • For higher doses (>80 g), consider administering over 3-5 days at 0.4 g/kg per day 1
  • Begin infusion at a slow rate and gradually increase if well tolerated 6
  • Monitor vital signs regularly during infusion, especially during the first 30 minutes 6

Premedication Recommendations

  • Diphenhydramine (Benadryl) 1 mg/kg 1
  • Acetaminophen (Tylenol) 10-15 mg/kg 1
  • Consider corticosteroids for patients with history of infusion reactions 1

Monitoring During Administration

  • Vital signs: temperature, blood pressure, heart rate, and respiratory rate 6
  • Signs of infusion reactions: headache, flushing, chills, nausea, chest tightness 4, 6
  • Renal function: urine output and serum creatinine 1

Management of Adverse Reactions

  • For mild reactions (headache, nausea): temporarily slow or pause infusion 4
  • For moderate reactions (fever, vomiting): pause infusion, administer additional antipyretics/antihistamines, resume at slower rate when symptoms resolve 4
  • For severe reactions (anaphylaxis, severe hypotension): stop infusion immediately, administer epinephrine, notify physician 1, 4

Special Considerations

  • Patients receiving first-time infusions require closer monitoring due to higher risk of adverse reactions 6
  • Elderly patients and those with renal impairment may require slower infusion rates and lower doses 3
  • For patients with fluid overload risk, consider more concentrated IVIG preparations (10%) and slower infusion rates 3
  • The half-life of IVIG is approximately 21-36 days, which guides dosing frequency for maintenance therapy 3

Post-Administration Monitoring

  • Monitor for delayed adverse reactions for 24-48 hours post-infusion 4
  • Assess clinical response based on indication-specific parameters 1, 3
  • For replacement therapy, maintain trough IgG levels between 8-12 g/L 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Intravenous Immunoglobulin (IVIG) Dosage and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.